GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
51.02
-1.35 (-2.58%)
At close: Nov 16, 2026, 4:00 PM EST
51.51
+0.49 (0.96%)
After-hours: Nov 16, 2026, 7:47 PM EST

GeneDx Holdings Statistics

Total Valuation

GeneDx Holdings has a market cap or net worth of $1.53 billion. The enterprise value is $1.57 billion.

Market Cap1.53B
Enterprise Value 1.57B

Important Dates

The last earnings date was Monday, November 9, 2026, after market close.

Earnings Date Nov 9, 2026
Ex-Dividend Date n/a

Share Statistics

GeneDx Holdings has 29.97 million shares outstanding. The number of shares has increased by 4.13% in one year.

Current Share Class 29.97M
Shares Outstanding 29.97M
Shares Change (YoY) +4.13%
Shares Change (QoQ) +0.57%
Owned by Insiders (%) 1.85%
Owned by Institutions (%) 79.08%
Float 20.59M

Valuation Ratios

PE Ratio n/a
Forward PE 53.25
PS Ratio 3.32
Forward PS 2.85
PB Ratio 6.25
P/TBV Ratio 14.54
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.42
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.88.

Current Ratio 4.16
Quick Ratio 3.67
Debt / Equity 0.88
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -15.01

Financial Efficiency

Return on equity (ROE) is -41.36% and return on invested capital (ROIC) is -22.16%.

Return on Equity (ROE) -41.36%
Return on Assets (ROA) -7.72%
Return on Invested Capital (ROIC) -22.16%
Return on Capital Employed (ROCE) -13.86%
Weighted Average Cost of Capital (WACC) 13.52%
Revenue Per Employee $354,449
Profits Per Employee -$85,422
Employee Count1,300
Asset Turnover 0.90
Inventory Turnover 8.92

Taxes

Income Tax -159,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -60.16% in the last 52 weeks. The beta is 1.99, so GeneDx Holdings's price volatility has been higher than the market average.

Beta (5Y) 1.99
52-Week Price Change -60.16%
50-Day Moving Average 73.13
200-Day Moving Average 69.67
Relative Strength Index (RSI) 34.88
Average Volume (20 Days) 1,140,257

Short Selling Information

The latest short interest is 6.55 million, so 21.86% of the outstanding shares have been sold short.

Short Interest 6.55M
Short Previous Month 6.02M
Short % of Shares Out 21.86%
Short % of Float 31.82%
Short Ratio (days to cover) 8.04

Income Statement

In the last 12 months, GeneDx Holdings had revenue of $460.78 million and -$111.05 million in losses. Loss per share was -$3.76.

Revenue460.78M
Gross Profit 316.85M
Operating Income -63.06M
Pretax Income -111.21M
Net Income -111.05M
EBITDA -36.66M
EBIT -63.06M
Loss Per Share -$3.76
Full Income Statement

Balance Sheet

The company has $170.12 million in cash and $215.38 million in debt, with a net cash position of -$45.27 million or -$1.51 per share.

Cash & Cash Equivalents 170.12M
Total Debt 215.38M
Net Cash -45.27M
Net Cash Per Share -$1.51
Equity (Book Value) 244.69M
Book Value Per Share 8.17
Working Capital 225.49M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$75.08 million and capital expenditures -$26.14 million, giving a free cash flow of -$101.22 million.

Operating Cash Flow -75.08M
Capital Expenditures -26.14M
Depreciation & Amortization 26.40M
Net Borrowing 85.43M
Free Cash Flow -101.22M
FCF Per Share -$3.38
Full Cash Flow Statement

Margins

Gross margin is 68.76%, with operating and profit margins of -13.68% and -24.10%.

Gross Margin 68.76%
Operating Margin -13.68%
Pretax Margin -24.13%
Profit Margin -24.10%
EBITDA Margin -7.96%
EBIT Margin -13.68%
FCF Margin n/a

Dividends & Yields

GeneDx Holdings does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -4.13%
Shareholder Yield -4.13%
Earnings Yield -7.38%
FCF Yield -6.61%

Analyst Forecast

The average price target for GeneDx Holdings is $82.00, which is 60.72% higher than the current price. The consensus rating is "Strong Buy".

Price Target $82.00
Price Target Difference 60.72%
Analyst Consensus Strong Buy
Analyst Count 8
Revenue Growth Forecast (3Y) 17.10%
EPS Growth Forecast (3Y) -2.19%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.

Last Split Date May 4, 2023
Split Type Reverse
Split Ratio 1:33

Scores

GeneDx Holdings has an Altman Z-Score of 2.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.75
Piotroski F-Score 3